Clinical trials: Type II Diabetic Patients With Nephropathy
Diabetic Kidney Disease
Antiproteinuric Effects of Liraglutide Treatment
The purpose of the study is to determine the effect of Liraglutide on albuminuria in type 2 diabetes.
- Trial name
- LIRALBU (NCT02545738)
- Testing
- Liraglutide
- Where
- Denmark
- Volunteers
- 32 people
- Sponsor
- Steno Diabetes Center Copenhagen
Diabetic Foot, Type 2 Diabetes Mellitus With Established Diabetic Nephropathy
The Effectiveness of Improving Self-care After Counseling for the Diabetics Mellitus Foots Around Chiayi Region
Objectives: Preventing diabetic foot problems (DFP) and associated consequences, such as amputation, is a critical in rural regions.
- Trial name
- NCT01299246
- Testing
- Michigan Neuropathy Screening Instrument
- Where
- Taiwan
- Volunteers
- 386 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Diabetic Nephropathies
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
PF-00489791 is an inhibitor of phosphodiesterase type 5. Our hypothesis is that PF-00489791 will enhance the relaxation of blood vessels within the kidney and so reduce blood pressure, improving renal function.
- Trial name
- NCT01200394
- Testing
- PF-00489791
- Where
- 160 sites in United States, Australia and 13 more
- Volunteers
- 256 people
- Sponsor
- Pfizer
Chronic Kidney Diseases, Diabetes Mellitus, Type 2
Stem Cell Therapy for Chronic Kidney Disease
The purpose of this study is to assess the safety and tolerability of allogeneic mesenchymal stem / stromal cell therapy in individuals with chronic kidney disease.
- Conditions
- Chronic Kidney Diseases, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes Mellitus
- Trial name
- NCT04869761
- Testing
- Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion, Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- LaTonya J. Hickson
Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
This study assesses the efficacy of bardoxolone methyl relative to placebo in delaying progression to end-stage renal disease (ESRD) and cardiovascular deaths in patients with Stage 4 Chronic Kidney Disease (CKD) and type 2…
- Trial name
- BEACON (NCT01351675)
- Testing
- Bardoxolone Methyl: 20 mg
- Volunteers
- 2,185 people
- Sponsor
- Biogen
Chronic Kidney Disease, Type 2 Diabetes
Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease
This study assesses the effects of bardoxolone methyl (RTA 402) in patients with type 2 diabetes and chronic kidney disease.
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes, Diabetic Nephropathy
- Trial name
- NCT00811889
- Testing
- Bardoxolone Methyl (RTA 402)
- Where
- 42 sites in United States
- Volunteers
- 227 people
- Sponsor
- Biogen
Diabetes
Aspirin and Renal Disease Progression in Patients With Type 2 Diabetes
The pathophysiology of diabetes is multifactorial. Beyond genetic susceptibility loci, a lot of acquired risk factors are involved in the development and progression of the disease.
- Trial name
- LEDA (NCT02895113)
- Testing
- Aspirin
- Where
- Italy
- Volunteers
- 418 people
- Sponsor
- University of Roma La Sapienza
Type 2 Diabetes Mellitus, Diabetic Nephropathy
Effects of Spironolactone Combination Therapy on Proteinuria, Kidney Function, and Blood Pressure
The detrimental effects of aldostrone are not adequately arrested by the use of angiotensin converting enzyme (ACE), angiotensin II receptor blocker (ARB) or a combination of both.
- Conditions
- Type 2 Diabetes Mellitus, Diabetic Nephropathy, Essential Hypertension
- Trial name
- NCT01667614
- Testing
- spironolacone 25 mg tablets added to losartan
- Where
- Iran
- Volunteers
- 136 people
- Sponsor
- Tehran University of Medical Sciences
Type2 Diabetes, Diabetic Kidney Disease
Efficacy of a High-intensity Physical Activity Program on Renal Function in High Risk Patients With Type 2 Diabetes
Type 2 diabetes is a chronic condition whose prevalence is increasing globally. Kidney disease is a key complication of diabetes and is among the most common cause of end-stage renal disease, requiring renal replacement therapy.
- Trial name
- ACTIDIANE (NCT03184662)
- Testing
- HIPA, Counseling PA
- Where
- 20 sites in Belgium, France
- Volunteers
- 178 people
- Sponsor
- Poitiers University Hospital
Diabetic Nephropathy
Matrix Metalloproteinases in Atherosclerosis of Chronic Kidney Disease
The purpose of this study is to determine whether matrix metalloproteinases are associated with atherosclerosis in the different stages of chronic kidney disease.
- Trial name
- MMACKD (NCT01458158)
- Where
- Greece
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Aristotle University Of Thessaloniki
IgA Nephropathy, Focal Segmental Glomerulosclerosis
Atrasentan in Patients With Proteinuric Glomerular Diseases
The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.
- Conditions
- IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease
- Trial name
- AFFINITY (NCT04573920)
- Testing
- Atrasentan
- Where
- 33 sites in United States, Australia and 4 more
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus, Chronic Kidney Disease
A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease
The purpose of the present study is to assess the safety and efficacy of up to 2 injections of REACT given 6 months (+4 weeks) apart (maximum).
- Trial name
- NCT03270956
- Testing
- Renal Autologous Cell Therapy (REACT)
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Prokidney
Diabetes Mellitus, Type 2, Diabetic Kidney Disease
Renohemodynamic Effects of Combined empagliflOzin and LosARtan
Worldwide, diabetic kidney disease (DKD) is the most common cause of chronic and end stage kidney disease. In parallel with the ever-increasing rates of obesity and type 2 diabetes (T2D), the incidence of DKD is expected to…
- Trial name
- RECOLAR (NCT04238702)
- Testing
- Empagliflozin 10 MG, Losartan 50Mg Tab
- Where
- Netherlands
- Volunteers
- 24 people
- Sponsor
- Amsterdam UMC, location VUmc
Diabetic Kidney Disease, Diabetic Nephropathy
A Study in Participants With Diabetic Kidney Disease
The purpose of this study is to determine if LY2382770 is safe and effective at protecting kidney function in participants with kidney disease due to diabetes.
- Conditions
- Diabetic Kidney Disease, Diabetic Nephropathy, Diabetic Glomerulosclerosis
- Trial name
- NCT01113801
- Testing
- LY2382770
- Where
- 78 sites in United States, Australia and 5 more
- Volunteers
- 417 people
- Sponsor
- Eli Lilly and Company
Sleep Apnea, Diabetic Nephropathy Type 2
Sleep Apnea, Coronary Atherosclerosis and Heart Failure in Diabetes Patients With Nephropathy
Background: Diabetes, and especially diabetic kidney disease is associated with the development of cardiovascular disease such as calcification in the coronary arteries and heart failure.
- Conditions
- Sleep Apnea, Diabetic Nephropathy Type 2, Coronary Atheroscleroses, Heart Insufficiency
- Trial name
- SLEEP (NCT04549324)
- Where
- Denmark
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Diabetic Kidney Disease
SER150 vs Placebo in Diabetic Kidney Disease
This study is to assess the efficacy and safety of SER150 administered for 24 weeks as a 15 mg twice a day BID dose (except on Day 168 15 mg QD) in participants with type 2 diabetes (T2D) and albuminuria in treatment with either…
- Trial name
- NCT04881123
- Testing
- SER150
- Where
- 12 sites in Australia, New Zealand
- Volunteers
- 20 people
- Sponsor
- Serodus AS
Diabetes Mellitus
Assessment of Serum Magnesium Level with Diabetic Foot Ulceration in Type II Diabetes Associated with Diabetic Nephropathy Patients
Magnesium (Mg), is the fourth most common cation in the body, with an essential role in fundamental biological reactions, whose deficiency provokes biochemical and symptomatic alterations in the human organism.
- Trial name
- NCT06754878
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Assiut University
Diabetes Mellitus Type 2
Patients With Type 2 Diabetes
Diabetes mellitus
- Trial name
- NCT07245082
- Where
- Taiwan
- Volunteers
- 2,000 people
- Sponsor
- National Taiwan University Hospital
CKD, Diabetic Kidney Disease
Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
This randomized study evaluates the effect of subcutaneous semaglutide /in combination with lifestyle counseling in patients with type 2 diabetes mellitus (T2DM), overweight/obesity, and stage 4-5 chronic kidney disease (CKD) or…
- Conditions
- CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese, Obesity
- Trial name
- RAISE-KT (NCT04741074)
- Testing
- Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Geisinger Clinic